Article
A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C.
Clinical and molecular hepatology - 1 Sept 2012
You Byung Chul, Kim Young Seok, Kim Hun il, Kim Se Hun, Park Seung Sik, Seo Yu Ri, Kim Sang Gyune, Lee Se Whan, Kim Hong Soo, Jeong Soung Won, Jang Jae Young, Kim Boo Sung
Abstract excerpt
BACKGROUND/AIMS: When combined with pegylated interferon alpha-2b (Peg-IFN α-2b) for the treatment of genotype 1 chronic hepatitis C (CHC) in Korea, the current guideline for the initial ribavirin (RBV) dose is based on body weight. However, since the mean body weight is lower for Korean patients than for patients in Western countries, current guidelines might result in Korean patients being overdosed with RBV....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.